Objective To explore the safety and effectiveness of nafamostat mesylate (NM) as an anticoagulant for hemodialysis, and its impact on the systemic coagulation function in patients undergoing maintenance hemodialysis (MHD). Methods A prospective study was conducted on 12 MHD patients at the Department of Nephrology, The First People's Hospital of Chengdu from January to September 2022. Blood samples were collected at various time points: before dialysis at the arterial end, during dialysis (1h, 2h, 3h and 4h) and 15 minutes post-dialysis at the sites before the filter, after the filter and at the arterial end. NM concentration and activated clotting time (ACT) were measured in these blood samples. Results At the time points of 1h, 2h, 3h and 4h during dialysis, the ACT values showed significant differences in the blood samples before the filter, after the filter and from arterial end (F=21.899, 27.464, 8.264 and 8.162 respectively; P<0.001, <0.001, =0.001 and =0.001 respectively); the ACT values of different sites at the same time point showed that the ACT value of arterial end was the lowest, followed by the value after filter and then the value before filter. At the time points of 1h, 2h, 3h and 4h during dialysis, the NM blood concentrations were significantly different in the blood samples before the filter, after the filter and from arterial end (F=46.547, 20.059, 16.582 and 16.687 respectively; P <0.001); the NM blood concentrations of different sites at the same time point showed that the NM blood concentration of arterial end was the lowest, followed by the value after filter and then the value before filter. Conclusion Nafamostat mesylate effectively serves as an anticoagulant in the extracorporeal circulation during hemodialysis. It possesses the characteristics of high dialysis clearance rate and rapid metabolism in the body with a minimal impact on systemic coagulation status. It is a new choice of anticoagulant for patients undergoing hemodialysis with high risk of bleeding.
AO Guang-Yu
,
HUANG Lan
,
CHEN Ting-Yu
,
LI Han-Yu
,
CHEN Min
. Observation on the anticoagulant efficacy and blood concentration of nafamostat mesylate in hemodialysis[J]. Chinese Journal of Blood Purification, 2023
, 22(08)
: 579
-583
.
DOI: 10.3969/j.issn.1671-4091.2023.08.003
1. Claudel SE, Miles LA, Murea M. Anticoagulation in hemodialysis: A narrative review. Semin Dial. 2021;34(2):103-115.
2. Abdel Azim ABE, ElSaid TW, El Said HW, et al. A randomized controlled clinical trial of 4% sodium citrate versus heparin as locking solution for temporary dialysis catheters among hemodialysis patients?. Clin Nephrol. 2018;90(5):341-349.
3. Lang Y, Zheng Y, Qi B, et al. Anticoagulation with nafamostat mesilate during extracorporeal life support. Int J Cardiol. 2022;366:71-79.
4. Kamijo H, Mochizuki K, Nakamura Y, et al. Nafamostat Mesylate Improved Survival Outcomes of Sepsis Patients Who Underwent Blood Purification: A Nationwide Registry Study in Japan. J Clin Med. 2020;9(8):2629.
5. 北村伸哉 , 张凌 . 甲磺酸萘莫司他在连续性肾脏替代治疗 中的抗凝应用 [J]. 华西医学 , 2018, 33(7): 801-805.
6. 孙献坤 王 芳 陈志文 张 凌. 甲磺酸萘莫司他抗凝在连续性肾脏替代治疗的应用进展[J]. 中国血液净化, 2022, 21(11): 827-830.
7. Fuse I, Higuchi W, Toba K, Aizawa Y. Inhibitory mechanism of human platelet aggregation by nafamostat mesilate. Platelets. 1999 Jul;10(4):212-218.
8. Ohtake Y, Hirasawa H, Sugai T, et al. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol, 1991, 93(93): 215-217
9. Miyata M, Shirakawa T, Acharya B, Terao S, Gotoh A. Effects of nafamostat mesilate on ADP-induced platelet aggregation and disaggregation in hemodialysis patients. ASAIO J. 2006 May-Jun;52(3):272-275.
10. 中国药典委员会. 中华人民共和国药 典（一部）2015版［Ｍ］.北京：中国医药科技出版社，2015：45-148.
11. Chazot C, Jean G. End-Stage Kidney Patients Require Hemodialysis Therapy Full Start. Blood Purif. 2019;47(1-3):214-222.
12. 茹海凤,闵筱兰,罗学文,等. 出血倾向病人血液透析抗凝方法研究进展[J]. 护理研究,2009,23(2):100-101.
13. Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis. 1985;15(3):164-168.
14. Abe M, Shiga H, Tatsumi H, et al. Results of the 2018 Japan Society for Blood Purification in Critical Care survey: current status and outcomes. Ren Replace Ther. 2022;8(1):58.
15. 中华医学会肾脏病学分会专家组. 连续性肾脏替代治疗的抗凝管理指南[J]. 中华肾脏病杂志,2022,38(11):1016-1024.
16. 赵煜松,曾海霞,孙卓.LC-MS/MS法测定甲磺酸萘莫司他有关物质[J].智慧健康,2021,7(01):116-118+121.
17. Oh HS, Kim T, Gu DH, et al. Pharmacokinetics of Nafamostat, a Potent Serine Protease Inhibitor, by a Novel LC-MS/MS Analysis. Molecules. 2022;27(6):1881.
18. Miyatake Y, Makino S, Kubota K, Egi M, Mizobuchi S. Association between Intra-Circuit Activated Clotting Time and Incidence of Bleeding Complications during Continuous Renal Replacement Therapy using Nafamostat Mesilate: a Retrospective Pilot Observational Study. Kobe J Med Sci. 2017;63(1):E30-E36.
19. Nakae H, Tajimi K. Correlation between serum nafamostat mesilate and activated coagulation time during continuous hemodiafiltration. Artif Organs. 2005 Apr;29(4):352-354.
20. Japan's health ministry.The heavy drug side effects disease response manual: systemic allergic reaction[M].(2010-06-25)[2018-06-01].http://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1h01.pdf.
21. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin[J]. Biochim Biophys Acta, 1981, 661(2): 342-345.
